Adjuvant TACE in HCC With High-risk Recurrence Factors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Adjuvant TACE in HCC With High-risk Recurrence Factors — Stella

Recruiting

Back to Hepatocellular Carcinoma trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Guangxi Medical University Cancer Hospital, Nanning

Key details

Phase

Large-scale testing

Sponsor

Guangxi Medical University

Enrollment target

~442 participants

Started

February 2026

Primary completion

December 2029

Age range

18 Years – 70 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov